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1. INTRODUCTION 
        
The discipline of medicinal chemistry is devoted to the discovery and development of 
new agents for treating diseases. Medicinal chemistry and pharmaceutical chemistry are 
disciplines at the intersection of chemistry, especially synthetic organic chemistry, and 
pharmacology and various other biological specialities, where it is involved with design, 
chemical synthesis and development for market of pharmaceutical agents (drugs)
1
.  Just as in 
all fields of science, the history of medicinal chemistry is comprised of the ideas, knowledge 
and available tools that have advanced contempory knowlegde
2
. The pharmaceutical 
chemistry is being concerned primarily with modification of stuctures having known 
physiological or pharmacological effects with analysis of drugs. 
        No discussion of the evolution of medicinal chemistry would be complete without 
briefly mentioning combinatorial chemistry and high though out screening. Significant 
advances in X-rays crystallography and nuclear magnetic resonance have made it possible to 
obtain detailed representatives of enzymes and other drug receptors. Statistical methods based 
on the correlation of physiological properties with biological potency are used to explain and 
optimize biological activity. 
       To provide an understanding of principles of medicinal chemistry, it is necessary to 
consider the physiological properties used to develop new pharmaceutically active 
compounds and their mechanism of action, the drugs metabolism including possible 
biological activities of metabolites, the importance in stereochemistry in drug design and 
methods used to determine what “space” a drug occupies1. 
      The earliest drug discoveries were made by random sampling of higher plants, producing 
hundreds and thousands of new organic chemicals are prepared annually throughout the 
world, and many of them are entered into pharmacological screens to determine whether they 
have useful biological activity. Most recently, auromated high throughput screening systems 
utilizing cell culture systems with linked enzyme assays and receptor molecules derived from 
gene cloning have greatly increased the efficiency of random screening. It is now practical to 
srceen enormous libraries in a short period of time, obtained from combinatorial chemistry 
procedures, by the development and use of robotics and automation
1
.   
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        Flavonoids class of natural products has found significant role in pharmaceutical effects 
including leishmanicidal activity, anti HIV, vasodilator, antiviral, antioxidant, anti 
inflammatory
3
. Still chemical modification of drug molecules to locate the member of the 
series having optimal effect has long been carried out, widely and will probably continue to 
be factor necessary to drug discovery
4
. 
       Flavonoids are groups of polyphenolic compounds which are widely distributed 
throughout the plant kingdom. To date about 3000 varieties of flavonoids are known. Many 
have low toxicity in medicine for maintainance of capillary integrity
8
. They are integral 
components of comman diet present in fruits, vegatables, olive oil, tea and red wine. It was 
demonstrated that flavonoids posses anxiolytic, anti-inflammatory, antiviral, antiprotozoal 
and anticarcinogenic activities. Moreover, a number of studies have suggested that flavonoids 
may display a protective role in the prevention of cancer, coronary heart diseas, bone loss and 
many other age related disease. 
      This of plants pigment in most angiosperm families, largely responsible for the colours 
including all parts of the plant and have important role in the growth and development of 
plants, protection against UV-B radiation forming antifungal barriers, antimicrobial, 
insecticidal estrogenic activities and helps in plant reproduction
5
. They are produced as a 
result of stressors that include climate, UV radiation, herbivorous and pathogen
6
. Over 4000 
flavonoids compounds have been characterized and classified according to chemical 
structure
5
. Therefore, a general synthetic method and combinatorial synthesis of these 
molecules would be desirable. In recent years, scientific and public interest in flavonol has 
grown enormously due to their putative beneficial effects against atherosclerosis, 
osteoporosis, diabetes mellitus and certain cancer. Flavonols intake in the  form of dietary 
supplements and plant extracts has been steadily increasing
7
. 
1.1 BASIC NUCLEUS: 
          Heterocyclic compounds are containing a ring structure with atoms in addition to 
carbon, such as sulphur, oxygen or nitrogen, as a part of ring. They may either have simple 
aromatic or non-aromatic ring, with a wide range of biological properties. The unique 
position occupied by heterocyclics in life processes has attracted much attention in the 
chemical, biochemical, medical, agriculture science and cognate branch of science and 
technology. 
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         Flavonoids occurs as aglyclone, glycosides and methylated derivatives. In plants, 
flavonoids aglycones (i.e- flavonoids without attached sugar) occur in a variety of structural 
forms. All contain fifteen carbon atoms in their basic nucleus: two six membered rings linked 
with a three carbon unit which may or may not be a part of a third ring
10
. The flavonoid 
aglycone consists of a benzene ring condensed with a six membered ring, which in the 2-
position carries a phenyl ring as a substituent. The six member ring condensed with the 
benzene ring is either a ϒ-pyrone (flavonols and flavonones) or its dihydroderivative 
(flavanols and flavanones). The position of the benzenoid substituent divides the flavonoid 
class into flavonoids (2-position) and isoflavonoids (3-position). Flavonols differ from 
flavonones by hydroxyl group the 3-position and a C2-C3 double bonds
9
. Flavonoids are often 
hydroxylated in position 3, 5, 7, 2’, 3’, 4’, 5’. Methylethers and acetylesters of the alcohol 
group are known to occur in nature. When glycosides are formed, the glycosidic linkage is 
normally located in positions 3 or 7 and the carbohydrate can be L-rhamnose, D-glucose, 
glucor-hamnose, galactose or arabinose
11
.  
         Chromones react with electrophiles at the exocylics oxygen atom, and can be cleaved 
by reaction with sodium hydroxide, ammonia and other nucleophiles (eg- reaction with 
hydrazine). Flavonoids dissolve in basic solution, resulting in a yellow color, which increases 
with pH anh the number of hydroxyl griups, but appears to be colorless solution upon 
addition of acid. It is soluble in sulphuric acid and it forms crystalline hydrochloride, when 
hydrogen chloride is passed into an ethereal solution of compounds
11
. 
         Flavonoids may be divided into six different major classes (flavones, isoflavones, 
flavonols, flavononols, flavonones and anthocyanidins), this is based on differences in 
molecular backbone structure
8
. 
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 1.2 STRUCTURE ACTIVITY RELATIONSHIP: 
 Flavanoids are benzo-γ-pyrone derivatives consisting a benzene ring-A and B 
comprising oxygen containing pyran ring C. The authors propose that small structural 
differences in the compounds are critical to their activity and their low toxic potential. 
Several structural determinants for flavanoids have been proposed include:- 
 The O-dihydroxy (catechol) structure in ring-B, which is the target of radicals for all 
the flavanoids with a saturated 2, 3-double bond. 
O
O
OH
OH
OH
OH
OH
 
 The 2, 3-double bond in conjugation with a 4-oxo function which is responsible for 
electron delocalization from the ring -B. 
 The additional presence of both 3 and 5 hydroxyl groups for maximum radical 
scavenging potential and strong radical absorption
12
. 
O
O
OH
OH
OH
OH
OH
OH  
 The presence of 5, 7, 4’ hydroxyl group along with double bond between C2 and C3 
and presence of oxo group at C4 is essential for Vascular relaxation
13
. 
 The order of potency for Vascular relaxation was Flavones > Flavonols > Isoflavones 
> Flavonones > Flavononol > Chalcones
13
. 
 The hydroxyl group on 3’ and 4’ position of ring A possessed high hydroxyl 
scavenging activity but ring B having more than ring A
14
. 
 The hydroxyl group or glucoside on 3 position of ring C also has scavenging ability15. 
 In Flavonols, Galagin introduction of 4’ – Fluorine, 2’ – Chlorine, 4’ – Chlorine not 
improves but introduction of 4’ -  Iodine increases the Anti Cancer activity15. 
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 The distance between A and C rings should be 6.9 Ao including 4 – oxo and 7 – 
hydroxyl moieties for Anti-inflammatory activity
16
. 
 Replacing the –OH groups with –OCH3 or -COOCH3 groups will cause complete 
loss of activity
17
. 
 Flavanoids lacking –OH groups on their B ring are more active against 
microorganisms than those with the –OH groups; this findings supports the idea that 
their microbial target is the membrane. 
  The presence of methoxy group at 4’ position shows Anti-hypergylcemic activity18. 
 The presence of hydroxyl groups at 2’, 3’, 4’, 3, 6, 7, and 8 shows good Anti-
hypergylcemic activity. 
 To enhance free radical scavenging activities of Flavonoids two structural factors are 
essential
18
, 
a) Catechol moiety is necessary. 
b) Presence of double bond between C2 – C3 and C4 – oxo function in ring C, namely 
pyrone moiety. 
                 Literature survey reveals that flavan-4-ones are well known for their varied 
pharmacological and microbiological activities. The high structural specificities makes 
flavanols an interesting class of molecules for medicinal chemistry study, since the structural 
units have a profound effect on biological activity
15
. In view of the above mentioned facts 
and continuation of our work on the synthesis of biologically important heterocyclic 
compounds, research is divided into two parts. 
Part I. Focuses on the synthesis of various 3-hydroxy flavone derivatives starting 
from commercially available starting materials. All the compounds 
synthesized were characterized by various spectroscopic methods i.e.: 
infrared (IR), ultraviolet (UV), mass spectroscopy (MS) and nuclear 
magnetic resonance (1H and 13C) 
Part II. On the anti bacterial, antiinflammatory and antidiabetic properties and the 
effect of synthesized 3-hydroxy flavone which will be studied. 
 
 
INTRODUCTION 
 
Nandha College Of Pharmacy And Research Institute, Erode Page 7 
 
1.3 DIABETES MELLITUS: 
           Diabetes Mellitus is a chronic metabolic disorder characterized by a high blood 
glucose concentration – hyperglycaemia (fasting plasma glucose > 7.0 mmol/l, or plasma 
glucose > 11.1 mmol/l 2 hours after a meal) – caused by insulin deficiency, often cobined 
with insulin resistance
19
. The risk of diabetic complication includes many particularly 
cardiovascular diseases, peripheral vascular disease. Complications such as coronary artery 
disease, strke, neuropathy, renal failure, retinopathy amputations and blindness are known to 
be associated with Diabetes Mellitus. Hyperglycaemia occurs because of uncontrolled hepatic 
glucose output and reduced uptake of glucose by skeletal muscle with reduced glycogen 
synthesis
20
.  
            Diabetes Mellitus is a chronic condition characterized by major derangements in 
metabolism of glucose and abnormalities in metabolism of fat, protein. Presently there are 
different groups of oral hypoglycaemic agents for clinical use, having characteristic profiles 
of side effects. Management of diabetes without any side effects is still a challenge to the 
medical system. This leads to increasing demand for natural products with antidiabetic 
activity having fewer side effects. 
1.3.1 CLASSIFICATION OF DIABETES MELLITUS:  
Insulin dependent Diabetes Mellitus ( IDDM-Type I) 
             Type 1 diabetes is a autoimmune disease. In diabetes, the immune system attacks the 
insulin producing beta cells in the pancreas and destroys them. It is clearly associated with all 
absolute deficiency of insulin secretion. The patients are usually young (children or 
adolescents) and not obese when they first develop symptoms. Viral infection may damage 
pancreatic beta cells and expose antigens that initiate a self perpetuating autoallergic 
process
21.
 
Non-Insulin dependent Diabetes Mellitus ( NIDDM-Type II) 
             The most comman form of diabetes is type 2 diabetes. About 90 to 95 % of people 
with diabetes have type 2. Non insulin dependent Diabetes Mellitus usually occurs after the 
age of forty
22
. This form of diabetes is associated with older age, obesity, family history of 
diabetes, previous history of gestational diabetes, physical inactivity and ethnicity. About 80 
% of people with type 2 diabetes are overweight. Type 2 diabetes is accompanied both by 
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insulin resistance and by impaired insulin secretion, each of which are important in its 
pathogenisis
19
. 
1.3.2 RISK FACTOR FOR TYPE 2 DIABETES 
23
: 
Obesity  
          Greater weight means a higher risk of insulin resistance, because fat interferes with the 
body’s ability to use insulin. 
Sedentary Lifestyle 
           The Surgeon General’s Report on Physical Activity and health (USA, 1996) states that 
“a sedentary life style is damaging to health and bears responsibility for the growing obesity 
problems”. 
Unhealthy Eating Habits 
            Unhealthy eating contributes largely to obesity. Too much fat, not enough fiber and 
too many simple carbohydrates all contribute to a diagnosis of diabetes. 
Family History and Genetics 
            It appears that people who have family members who have been diagnosed with type 
2 diabetes are at a greater risk for developing it themselves. 
Increased Age 
            Scientists theorize that the pancreas ages right along with us, and doesn’t Pump 
insulin as efficiently as it did when we were younger. Also, as our cells age, they become 
more resistant to insulin as well. 
High Blood Pressure and High Cholesterol 
            These two bad boys are the hallmark risk factors for many diseases and conditions, 
including Type 2 diabetes. Not only do they damage your heart vessels but they are two key 
components in metabolic syndrome, a cluster of symptoms including obesity, a high fat diet 
and lack of exercise. Having metabolic syndrome increases your risk of heart disease, stroke 
and diabetes. 
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History of Gestational Diabetes 
              Gestational diabetes affects about 4 % of all pregnant women. It begins when 
hormones from the placenta make the mother insulin resistant. Many women who have 
gestational diabetes develop type 2 diabetes years later. Their babies are also at some risk for 
developing diabetes later in life. 
1.3.3 REGULATION OF GLUCOSE METABOLISM: 
               The facilitated diffusion of glucose into cells along a downhill gradient is ensured 
by glucose phosphorylation. This enzymatic reaction, the conversion of glucose to glucose-6-
phosphate, is accomplishedby one of a family of hexokinases. The four hexokinases are 
distributed differently in tissues, and two are regulated by insulin. Hexokinase IV, a 50,000 
dalton enzyme more commonly known as glucokinase gene, is found in association with 
GLUT 2 in liver and pancreatic beta cells. There is one glucokinase gene, but different first 
exons and promoters are employed in the two tissues. The liver glucokinase gene and 
Hexokinase II is regulated transcriptionally by insulin
24
.   
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1.4 INFLAMMATION: 
1.4.1 Definition  
            Inflammation is defined as the local response of living mammalian tissues to injury 
due to any agent. It is body defense reaction in order to remove the consequent necrosed cells 
and tissues well as to eliminate or limit the spread of injurious agent. Inflammation is a usual 
tissues reaction to physical, chemical or biological stress or injury. It manifests as an 
immunological response and amassing of inflammatory cells and play a role in both normal 
repair reactions and in the pathogenesis of disease. The inflammatory reactions are usually 
defined as acute or chronic on the basis of both their temporal duration and the prevailing 
phenomena. Inflammation is the body’s effort to inactivate or destroy invading organism, 
remove irritants and set the stage for tissue repair
25
. 
 The agent causing inflammation may be as order- 
1) Physical Agents like heat, mechanism trauma, cold, radiation. 
2) Chemical Agents like organic and inorganic poisons. 
3) Infective Agents like bacteria, viruses and their toxins. 
4) Immunological Agents like antigen antibody and cell mediated reaction. 
1.4.2 Signs of Inflammation
26
  
Five important signs of inflammation are, 
1) Rubor (redness)         2)  Calor (heat)         3)  Tumor (swelling) 
4) Dolor (pain)                5)  Laesa (loss of function) 
1.4.3 Causes  
 Burns 
 Chemical irritants 
 Frostbite 
 Toxins 
 Infection by pathogen 
 Necrosis 
 Physical injury, blunt or penetrating 
 Immune reactions due to hypersensitivity 
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 Ionizing radiation 
 Foreign bodies, including splinters and dirt. 
 
1.4.4 Types of Inflammation
27
  
Depending upon the defence capacity of the host and duration of response, inflammation can 
classified as Acute and Chronic. 
A) Acute Inflammation: 
                Infected ingrown toenail showing the characteristic redness and swelling associated 
with acute inflammation. Acute inflammation is a short-term process which is characterized 
by the classic signs of inflammation- swelling, redness, pain, heat and loss of function- due to 
the infiltration of the tissues by plasma and leukocytes. It occurs as long as the injurious 
stimulus is present and ceases once the stimulus has been removed, broken down, or walled 
off by scarring (fibrosis). The process of acute inflammation is initiated by the blood vessels 
local to the injured tissue, which alter to allow the exudation of plasma proteins and 
leukocytes into the surrounding tissue. The increased flow of fluid into the tissue causes the 
characteristic swelling associated with inflammation, and the increased blood flow to the area 
causes the reddened color and increased heat. 
B) Chronic Inflammation: 
                   Chronic inflammation is a pathological condition characterized by concurrent 
active inflammation, tissues destruction, and attempts at repair. Chronic inflammation is not 
characterized by the classic signs of acute inflammation listed above. Instead, chronically 
inflamed tissue is characterized by the infiltration of mononuclear immune cells (monocytes, 
macrophages, lymphocytes and plasma cells), tissue destruction, and attempts at healing, 
which include angiogenesis and fibrosis. Endogenous causes include persistent acute 
inflammation. Exogenous causes are varied and include bacterial infection, especially by 
Mycobacterium tuberculosis, prolonged exposure to chemical agents such as silica, or 
autoimmune reactions such as rheumatoid arthritis.  
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1.5 BACTERIAL  INFECTIONS: 
              In developing countries low levels of hygiene and sanitation exposed the 
susceptibility of people to opportunistic bacterial and fungal infections that increased 
dramatically the incidence and complications. Since last decade, there has been an increasing 
evidence of bacterial and fungal infections which proves the most critical problem due to 
population explosion, pollution, changed environmental conditions, wastes from different 
sources, which may affect food with perfect nutrition value. These factors cause less 
immunogenicity in human beings and animal
28
. Although prophylaxis and treatment 
strategies have been improved over the years, infections still contribute significantly to 
morbidity and mortility
29
. Owning to many advances in surgery, cancer treatment, solid organ 
and bone marrow transplantation, HIV epidemic and immune compromised patients, the 
severity has been still increasing
30
. 
                Also multiple drug resistance developed in microorganism has significantly been 
increased in recent years. Less immunogenicity coupled with the resistance of microbes to 
antibiotics with increased toxicity in humans being and animal during prolonged the 
treatment with several antimicrobial drugs. Therefore, the flavonoids may be promising new 
class compounds in antimicrobial therapy. The use of flavonoids against bacterial and fungus 
infections has two purposes: 
1) To kill the bacteria or fungus cells and 
2) To counteract the spread and the effects of the bacterial toxins.  
               Microbes producing extended spectrum β- lactamases, that are resistant to virtually 
all β- lactam have been reported (Methicillin – Resistant Staphylococcus auresus, 
Vancomycin – Resistant Enterococci, Antibiotic – Resistant Gram – Negative Bacilli), for 
these kind of microbes, flavonoids may be considered potential for these infections in the 
future. 
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The most comman microorganism responsible for disease include:- 
      Gram – positive bacterial species       Gram – negative bacterial species 
              Staphylococcus Spp: 
      S.aureus, S.epidermidi, S.albus 
                     Bacillus Spp: 
        B.cereus, B. fragile, B.subtilis,             
                    B.licheniformis 
                Strepyococcus Spp: 
   S.pyrogen, S.viridans, S.pneumoniae,    
                  S.baris, S.jaccali 
            Pseudomonas aeruginosa,    
                       Shigella boydii, 
                        K.pneumonia, 
                           B.cepacia, 
                     Salmonella typhi 
                      Escherichia coli.                                                           
 
Many but not all of the bacterial strains commonly encountered by humans are killed by 
flavonoids. Activities of flavonoids are more potent against Gram-positive bacterial species 
than Gram-negative bacteria
31
. 
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2. LITERATURE REVIEW 
Narayana et al., synthesis flavonoids as antioxidant and anti hepatotoxic agents. The synthesized 
compounds were screened for their free radical scavenging abilities
32
. 
 
    
O
OH
O         
HO OH
OH
OH
O  
 
Bansal et al., synthesis and anti-diabetic as well as antispasmodic activity of 6-chloro-3-hydroxy-
2-(2’-thienyl)-4-oxo-4H-1-benzopyran. The synthesized compounds were screened for their anti-
diabetic and antispasmodic activity
33
. 
 
Cl
O
S
O
OH
 
 
Li et al., synthesized libraries of flavonols made through Algar-Flynn-Oyamada reaction from 
2’-hydroxyacetophenone and benzaldehyde also studied for their potential pharmacological and 
biological activities of these compounds
34
. 
                                          R – R’ = H, CH3, OCH3 
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R O
O
R'
O O
OH
 
Olaleye et al., synthesis and anti-inflammatory as well as anti-nociceptive properties of 
flavonoids. The synthesized compounds were screened for their anti-inflammatory and anti-
nociceptive activity
35
. 
Carvalho et al., synthesis of new iodine derivatives of flavonol and isoflavone by using iodine, 
potassium hydroxide and methanol
36
. 
 
                     
O
OH
O
OCH3
OCH3
H3CO
I
I
 
 
Tapas et al., synthesis flavonoids as nutraceuticals. The synthesized compounds were screened 
for their anti-microbial and anti-bacterial activity
37
. 
Amic et al., described the relationship between the structural characteristics of flavonoids and 
their anti-oxidant activity and suggested the free radical scavenger potential of these 
polyphenolic compounds, also possible mechanism of action of flavonoids lacking B rings OHs 
as free radical scavengers has been proposed
38
. 
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        R3 – R8 = H, OH, Ogl                         R2 ‘– R5 ‘= H, OH, OCH3, Ogl 
 
                            
O
O
R3 '
R4 'R2 '
R7
R8
R5
R3
R5 '
  
 
Alvarenz et al., has studied synergism of some substituted flavonoids along with anti-microbial 
activity and established relationships between membranes structures of various microorganisms 
and effects of the compounds
39
. 
               R3 = OH, O-Rut                                  R2 ‘– R3 ‘= OH 
 
                         
O
R3 '
OHR2 '
OOH
HO
R3
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Xue et al., reported the first total synthesis of (+)-3’,7’-dihydroxy-4’-methoxyflavan, a naturally 
occurring flavan
40
. 
                        
O
O
HO
OCH3
OH
 
Cushnie et al., studied anti-microbial activity, anti-viral activity and anti-fungal activity of 
flavonoids, including mechanism of action of various flavonoids
30
. 
           2 – 6 = OH, OCH3, Cl                                  2’ – 6’ = OH, OCH3, Cl 
 
                       
O
O
1
2
3
45
6
7
8
3'
4'
5'
1'
2'
6'
 
Cespedes et al., synthesis and anti-inflammatory properties of flavonol from Aristotelia chilensis 
extracts. The synthesized compounds were screened for anti-inflammatory activity
41
. 
Bhsakar et al., synthesis, characterization and anti-bacterial activity of new series of prenyloxy 
chalcones and prenyloxy flavonones. The synthesized and tested for anti-bacterial effects against 
E.coli, S.auresus
42
. 
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OHO
O
R
 
Bylka et al., has presented a review of flavonoids that have a proven inhibitory activity against a 
variety of human pathogens, including anti-biotic resistant Gram-positive and Gram-negative 
strain of bacteria and viruses
43.
       
Boumendjel et al. studied the anti-mitotic and anti-proliferative activity of chalcones
44
. 
 R2 – R6 = H, OH, OCH3, OC2H5, F, Cl, NH2        R2 ‘– R6 ‘= H, OH, OCH3, OC2H5, Cl, NH2 
 
                        
R4
R6
R2
O
R2 ' R3 '
R4 '
R5 'R6 '
 
 
Nambi et al., have reported the anti-inflammatory activity of flavones and its hydroxy 
derivatives
45
. 
Conti et al., has reported the mechanism of action of the anti-rhinovirus flavonoid 4’,6-
Dicyanoflavan by inhibiting an early event of rhinovirus type 1B replication in Hela cells and 
suggested the stabilizing effects of Dicyanoflavan on virion capsid conformation is responsible 
for uncoating inhibition
46
. 
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Jayasree et al., has reported the anti-oxidant and anti-bacterial activity of new 3- methyl 
flavones
47
. 
Sivakumar et al., has studied the anti-tumor activity and anti-oxidant status of Caesalpinia 
bonducella against Ehrlich ascites carcinoma in swiss albino mice
48
. 
Chen et al., has reported photo chemical synthesis of 2,2’-Biflavonones from flavones with their 
anti- HIV, anti-viral activities
49
. 
 
                            
O O
O O  
 
Mewett et al., has reported synthesis and positive modulatory activities of a small library of 
flavan-3-ol derivatives on α1 β2ϒ2I GABAA receptor
50
. 
Ghotekar et al., described synthesis of biologically important chromones and pyrazolines
51
. 
                                            R1 – R4 = H, CH3, OCH3, Cl, F 
R2
R1
O
O
R3
R4
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Gorduza et al., syudied the structural reactivity relationship of anti-oxidant flavonoids suggesting 
anti-oxidant properties of hydroxyl flavones can be used in therapy of diseases generated or 
increased by radical mechanism oxidation and accumulation of radical O2
52
. 
 
HO O
OH O
OH
 
 
Vibhute et al., has reported new chalcones derivatives synthesis from 2-chloro-8-methoxy-
quinoline-3-carbaldehyde and halo hydroxyl substituted acetophenones via Clasien-schmidt 
screened for their anti-bacterial activity
53
. 
 
O
N
O
I
I Cl
OCH3
 
 
Sharma et al., has reported synthesis of dihydroxy chalcone derivative by microwaves. The 
synthesized compounds were screened for their anti-bacterial, anti-malarial and anti-
mycobacterial activities
54
. 
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Wankhade et al., has reported synthesis and anti-oxidant activity of some 3-Aroyl chromanone 
and Flavanones
55
. 
 
O
C
O
O
 
 
Kamal et al., has studied the synthesis and evaluation of new pyrrole[2,1-c] [1,4] benzodiazepine 
hybrids linked to a flavones moiety exhibiting significant DNA minor groove binding ability
56
. 
 
O
O
O (CH2)n-O
H3CCO
N
N
O
 
 
Witezak et al., studied the synthesis of analogues of various of natural C-glycosyl compounds : 
C-glycosyl flavonoids, Multustriatin, Hernandulcin and (1-4)-C- linked disaccharides from the 
new carbohydrate synthone levoglucosenone
57
. 
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O
OH
HO
O
OH
OH
OH
 
Pattan et al., has reported synthesis and biological evaluation of some new benzopyrones
58
. 
 
O
Cl
N
H
N
Ar
 
 
Zhao et al., reported synthesis and anti-depressant activites of series of 5,7-dihydroxy flavanones 
derivatives
59
. 
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HO O
OH
R
O  
Venkatesan et al., reported synthesis and anti-microbial activity of substituted chromone 
derivatives
60
. 
Tachakittirugrod et al., reported anti-oxidant activity of flavonoids isolated from Psidium 
guajava
61
. 
Marcel et al., reported anti-oxidant activity of flavonoids extracted from leaves and stems of 
Adenia lobata
62
. 
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3. AIM AND OBJECTIVE OF THE WORK 
 Current approaches in the treatment of hyperglycemia involve drug treatment with 
various classes of anti-diabetics. Major drawbacks of chemotherapy include adverse effects and 
drug resistance. Adverse effects associated with traditional anti diabetic drugs are hepatotoxicity 
and severe hypoglycemia. Therefore to overcome the shortcomings of the present treatment, an 
anti hyperglycemic drug with a new mechanism of action, capable of providing complete and 
safe treatment of diabetics mellitus. 
                       Drug designing is an important tool in the field of medicinal chemistry wherein the 
syntheses of new medicinal compounds are done by molecular or chemical manipulation of the 
lead moiety in order of producing a highly active compound. Thus, making gradual changes in 
physio-chemical properties of the lead moiety to enhance the biological activities. 
                      Literature survey reveals that 3-Flavonols are well known for their varied 
pharmacological activities. In view of the above mentioned facts and continuation of our work 
on the synthesis of biologically important Flavonoids compounds and to screen further following 
scheme. 
                     Encouraged by these reports and in continuation of our interest in the chemistry of 
3-flavanols, we have synthesized 2, 3-disubstituted flavan-4-ones by condensation of various 
chalcone derivatives with hydrogen peroxide in presence of absolute ethanol (95%) in the hope 
of getting potent pharmacological agents. The present project is aimed at the following, 
1. 3-hydroxy flavones is to be synthesized from acetophenone derivatives and 
corresponding aldehydes by Algar-Flynn-Oyamada reaction. 
2. To purify the final compounds by recrystallizing it using appropriate solvents. 
3. To identify the compounds by using Solubility, TLC and melting point determination. 
4. To characterize all the new compounds by analytical and spectral methods. 
5. To evaluate the synthesized compounds for their antihyperglycemic, anti inflammatory 
and antimicrobial activities. 
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4. PLAN OF WORK 
                          From the literature review reveals, that the flavanoids have a broad biological 
and pharmacological activities.
 
The present work was carried out to synthesize and characterize 
the flavanol derivatives; also to study the pharmacological activity. This work was carried out as 
outlined below. 
1. To synthesize of various chalcone derivatives using acetophenone derivatives as starting 
materials. 
2. To cyclocondense of chalcone derivatives to synthesize flavanoid derivatives. 
3. To characterize of synthesized intermediates and compounds quantitively 
a. Solubility data 
b. Melting Point data 
c. TLC analysis data  
d. Elemental analysis data 
e. Spectral studies like IR, NMR and Mass Spectra etc., 
4.  Evaluation of Synthesized compounds for the pharmacological activity. 
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5. MATERIALS AND METHODS 
 
                          All the synthetic work was done by using laboratory grade reagents and solvents. 
The solvents and reagents were purified and dried according to the procedure given in Vogel’s 
textbook of practical organic chemistry. All the compounds procured were purified dried, 
whenever necessary before use, following standard methods. 
● The compounds were purified by recrystallization using suitable solvents. 
● Solubility of all synthesized compounds in different solvents like Water, Ethanol, Acetone, 
Chloroform, DMSO, and Benzene was determined. 
● Melting point of synthesized compounds were determined in open capillary tubes. 
● TLC’s were performed to monitor the reactors, the reaction and to determine the purity of the 
products. Thin Layer Chromatography was checked by using silica gel-G coated plates. Iodine 
vapours are used as visualizing agent. 
● IR Spectra were recorded on Shimadzu 8400-S Fourier Transform Infrared Spectrophotometer 
using Potassium Bromide. (Vmax in cm
-1
). 
● 1H NMR spectra was recorded on Bruker NMR spectrophotometer using Acetone as solvent at 
Sri Ramachandra University, Chennai and chemical shifts are given in parts per million. 
● Mass Spectra were recorded at Sophisticated Analytical Instruments Facility at Indian Institute 
of Technology, Chennai. 
Animal approval  
 The study was conducted after obtaining the approval from Institutional animal ethics 
committee (IAEC), and the experimental procedures were in accordance to the guidelines of 
IAEC (688/02/c/CPCSEA). 
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6.1 Scheme of the Work 
Step 1 :- 
 
     (2 - Hydroxy                   (Aromatic                                                   (2-Hydroxy Chalcone 
      Acetophenone)                Aldehyde)                                                           Derivative) 
 
Step 2: – 
 
     (2-Hydroxy Chalcone Derivative)                         (2-Phenyl-3-Hydroxy-4H-Chroman-4-one)                                                                                                                                   
Step 3:– 
 
(2-Phenyl-3-Hydroxy-4H-Chroman-4-one)                     (2-Phenyl-3-Hydroxy-6,8-Diiodo-                 
                                                                                                    4H- Chroman-4-one) 
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6.2 SYNTHESIS OF COMPOUNDS 
COMPOUND A – Synthesis of 2-(4’-nitrophenyl)-3-hydroxy-4H-Chromen-4-one 
STEP 1 : Preparation of Chalcone Derivative  
Synthesis of 3-(4’-nitrophenyl)-1-(2-hydroxyphenyl)-prop-2-ene-1-one : 
               A mixture of 2-hydroxy Acetophenone (0.01) and p-nitro benzaldehyde (0.01) was 
stirred in 30 ml of absolute ethanol (95%) and then aqueous solution of potassium hydroxide 
was added to it. The reaction mixture was kept overnight at room temperature and then 
poured on crushed ice. The mixture was then neutralised with dil.HCl acid. The chalcone 
derivative precipitates out as solid that was filtered dried and recrystallised from ethanol and 
analysed. 
(2-Hydroxy Acetophenone)(4-Nitrobenzaldehyde)                          (2-Hydroxy Chalcone Derivative) 
 
STEP 2 : Cylisation of Chalcone Derivative and Addition of Hydroxyl group : 
Synthesis of 2-(4’-nitrophenyl)-3-hydroxy-4H-Chromen-4-one : 
                The intermediate, add 10 ml of hydrogen peroxide drop wise maintaining 
temperature 10 
o
C, stir for 2 hrs and then poured on crushed ice. The mixture was then 
neutralised with dil.HCl acid. The solid product was filtered, washed with ice cold water. 
(2-Hydroxy Chalcone Derivative)                                    2-(4’-nitrophenyl)-3-hydroxy-4H-Chromen-4-one 
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COMPOUND B – Synthesis of 2-(4-chlorophenyl)-7-methoxy-3-hydroxy-4H-Chromen-4-
one 
STEP 1: Preparation of Chalcone Derivative  
Synthesis of 3-(4’-chlorophenyl)-1-(2-hydroxy-4-methoxyphenyl)-prop-2-ene-1-one : 
                A mixture of 2-hydroxy-4-methoxy Acetophenone (0.01) and p-chloro 
benzaldehyde (0.01) was stirred in 30 ml of absolute ethanol (95%) and then aqueous 
solution of potassium hydroxide was added to it. The reaction mixture was kept overnight at 
room temperature and then poured on crushed ice. The mixture was then neutralised with 
dil.HCl acid. The chalcone derivative precipitates out as solid that was filtered dried and 
recrystallised from ethanol and analysed. 
(2-Hydroxy-4-Methoxy      (4-Chlorobenzaldehyde)                          (2-hydroxy-4-Methoxy Chalcone Drv.) 
    Acetophenone) 
 
STEP 2: Cylisation of Chalcone Derivative and Addition of Hydroxyl group: 
Synthesis of 2-(4’-chlorophenyl)- 3-hydroxy-7-methoxy-4H-Chromen-4-one : 
                  The intermediate, add 10 ml of hydrogen peroxide drop wise maintaining 
temperature 10 
o
C, stir for 2 hrs and then poured on crushed ice. The mixture was then 
neutralised with dil.HCl acid. The solid product was filtered, washed with ice cold water. 
(2-Hydroxy-4-Methoxy Chalcone Drv.)                                            2-(4-chlorophenyl)-7-methoxy-3-hydroxy 
                                                                                                                           4H-Chromen-4-one 
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COMPOUND C – Synthesis of 2-(2’-furfural)-3-hydroxy-4H-Chromen-4-one 
STEP 1: Preparation of Chalcone Derivative  
Synthesis of 3-(2’-furfural)-1-(2-hydroxyphenyl)-prop-2-ene-1-one : 
                A mixture of 2-hydroxy Acetophenone (0.01) and Furfuraldehyde (0.01) was 
stirred in 30 ml of absolute ethanol (95%) and then aqueous solution of potassium hydroxide 
was added to it. The reaction mixture was kept overnight at room temperature and then 
poured on crushed ice. The mixture was then neutralised with dil.HCl acid. The chalcone 
derivative precipitates out as solid that was filtered dried and recrystallised from ethanol and 
analysed. 
 
(2-Hydroxy Acetophenone)    (Furfuraldehyde)                                    (2-Hydroxy Furfural Chalcone Drv.) 
 
STEP 2: Cylisation of Chalcone Derivative and Addition of Hydroxyl group : 
Synthesis of 2-(2’-furfural)- 3-hydroxy-4H-Chromen-4-one : 
                  The intermediate, add 10 ml of hydrogen peroxide drop wise maintaining 
temperature 10 
o
C, stir for 2 hrs and then poured on crushed ice. The mixture was then 
neutralised with dil.HCl acid. The solid product was filtered, washed with ice cold water. 
 
     (2-Hydroxy Furfural Chalcone Drv.)                               2-(2’-fufural)-3-hydroxy-4H-Chromen-4-one) 
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COMPOUND D – Synthesis of 2-(2’-hydroxyphenyl)-3-hydroxy-4H-Chromen-4-one 
STEP 1: Preparation of Chalcone Derivative  
Synthesis of 3-(2’-hydroxyphenyl)-1-(2-hydroxyphenyl)-prop-2-ene-1-one : 
                 A mixture of 2-hydroxy Acetophenone (0.01) and Salicylaldehyde (0.01) was 
stirred in 30 ml of absolute ethanol (95%) and then aqueous solution of potassium hydroxide 
was added to it. The reaction mixture was kept overnight at room temperature and then 
poured on crushed ice. The mixture was then neutralized with dil.HCl acid. The chalcone 
derivative precipitates out as solid that was filtered dried and recrystallised from ethanol and 
analyzed. 
 
 (2-Hydroxy                        (2-Hydroxy benzaldehyde)                               (2-Hydroxy Chalcone Derivative)  
      Acetophenone) 
 
STEP 2 : Cylisation of Chalcone Derivative and Addition of Hydroxyl group : 
Synthesis of 2-(2’-hydroxyphenyl)- 3-hydroxy-4H-Chromen-4-one : 
                 The intermediate, add 10 ml of hydrogen peroxide drop wise maintaining 
temperature 10 
o
C, stir for 2 hrs and then poured on crushed ice. The mixture was then 
neutralised with dil.HCl acid. The solid product was filtered, washed with ice cold water. 
 
         (2-Hydroxy Chalcone Derivative)                                                2-(2’-hydroxyphenyl)-3-hydroxy-4H- 
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                                                                                                                                 Chromen-4-one 
COMPOUND E – Synthesis of 2-(4’-nitrophenyl)-7-methoxy-3-hydroxy-4H-Chromen-4-
one 
STEP 1: Preparation of Chalcone Derivative  
Synthesis of 3-(4’-nitrophenyl)-1-(2-hydroxy-4-methoxyphenyl)-prop-2-ene-1-one: 
              A mixture of 2-hydroxy-4-methoxy Acetophenone (0.01) and p-nitro benzaldehyde 
(0.01) was stirred in 30 ml of absolute ethanol (95%) and then aqueous solution of potassium 
hydroxide was added to it. The reaction mixture was kept overnight at room temperature and 
then poured on crushed ice. The mixture was then neutralised with dil.HCl acid. The 
chalcone derivative precipitates out as solid that was filtered dried and recrystallised from 
ethanol and analysed. 
 
    (2-Hydroxy-4-Methoxy         (4-Nitrobenzaldehyde)                      (2-Hydroxy-4-Methoxy Chalcone Drv.)  
         Acetophenone) 
STEP 2 : Cylisation of Chalcone Derivative and Addition of Hydroxyl group : 
Synthesis of 2-(4’-nitrophenyl)- 3-hydroxy-7-methoxy-4H-Chromen-4-one : 
                The intermediate, add 10 ml of hydrogen peroxide drop wise maintaining 
temperature 10 
o
C, stir for 2 hrs and then poured on crushed ice. The mixture was then 
neutralised with dil.HCl acid. The solid product was filtered, washed with ice cold water. 
        (2-Hydroxy-4-Methoxy Chalcone Drv.)                                            2-(4’-nitrophenyl)-3-hydroxy- 
                                                                                                                        7-methoxy Chromen-4-one 
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COMPOUND F – Synthesis of 2-(4’-methoxyphenyl)-3-hydroxy-4H-Chromen-4-one 
STEP 1: Preparation of Chalcone Derivative  
 Synthesis of 3-(4’-methoxyphenyl)-1-(2-hydroxyphenyl)-prop-2-ene-1-one: 
              A mixture of 2-hydroxy Acetophenone (0.01) Anisaldehyde (0.01) was stirred in 30 
ml of absolute ethanol (95%) and then aqueous solution of potassium hydroxide was added to 
it. The reaction mixture was kept overnight at room temperature and then poured on crushed 
ice. The mixture was then neutralised with dil.HCl acid. The chalcone derivative precipitates 
out as solid that was filtered dried and recrystallised from ethanol and analysed. 
 
 
(2-Hydroxy                      (4-Methoxy benzaldehyde)                                 (Hydroxy Chalcone Derivative) 
    Acetophenone) 
 
STEP 2 : Cylisation of Chalcone Derivative and Addition of Hydroxyl group : 
Synthesis of 2-(4’-methoxyphenyl)-3-hydroxy-4H-Chromen-4-one : 
                The intermediate, add 10 ml of hydrogen peroxide drop wise maintaining 
temperature 10 
o
C, stir for 2 hrs and then poured on crushed ice. The mixture was then 
neutralised with dil.HCl acid. The solid product was filtered, washed with ice cold water. 
      (Hydroxy Chalcone Derivative)                               2-(4-methoxyphenyl)-3-hydroxy-4H-Chromen-4-one 
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COMPOUND G – Synthesis of 2-(4-nitrophenyl)-6,8-diiodo-3-hydroxy-7-methoxy-4H-
Chromen-4-one 
STEP 1: Preparation of Chalcone Derivative  
Synthesis of 3-(4’-nitrophenyl)-1-(2-hydroxy-4-methoxyphenyl)-prop-2-ene-1-one : 
              A mixture of 2-hydroxy-4-methoxy Acetophenone (0.01) and p-nitro benzaldehyde 
(0.01) was stirred in 30 ml of absolute ethanol (95%) and then aqueous solution of potassium 
hydroxide was added to it. The reaction mixture was kept overnight at room temperature and 
then poured on crushed ice. The mixture was then neutralised with dil.HCl acid. The 
chalcone derivative precipitates out as solid that was filtered dried and recrystallised from 
ethanol and analysed. 
    (2-Hydroxy-4-Methoxy         (4-Nitrobenzaldehyde)                      (2-Hydroxy-4-Methoxy Chalcone Drv.)  
         Acetophenone) 
 
STEP 2 : Cylisation of Chalcone Derivative and Addition of Hydroxyl group : 
Synthesis of 2-(4’-nitrophenyl)- 3-hydroxy-7-methoxy-4H-Chromen-4-one : 
                The intermediate, add 10 ml of hydrogen peroxide drop wise maintaining 
temperature 10 
o
C, stir for 2 hrs and then poured on crushed ice. The mixture was then 
neutralised with dil.HCl acid. The solid product was filtered, washed with ice cold water. 
 
        (2-Hydroxy-4-Methoxy Chalcone Drv.)                                            2-(4’-nitrophenyl)-3-hydroxy-  
                                                                                                                        7-methoxy Chromen-4-one 
EXPERIMENTAL WORK 
 
Nandha College Of Pharmacy And Research Institute, Erode Page 35 
 
STEP-3: Addition of Iodine : 
 Synthesis of 2-(4’-nitrophenyl)-3-hydroxy-6,8-diiodo-7-methoxy-4H-Chromen-4-    one : 
                     The final product is dissolved in 10ml of Methanol,add Potassium 
Hydroxide(25mg) with stirring and add Iodine. Keep solution for room temperature, stir for 3 
hrs. Evaporate the solution to obtain the product. 
 
 
         2-(4’-nitrophenyl)-3-hydroxy-                                              2-(4’-nitrophenyl)-3-hydroxy-6,8-diiodo-7- 
         7-methoxy Chromen-4-one                                                                methoxy-4H-Chromen-4-one 
 
COMPOUND H – Synthesis of 2-(4’-nitrophenyl)-3-hydroxy-6,8-diiodo-4H-Chromen-4-one 
STEP 1 : Preparation of Chalcone Derivative  
 Synthesis of 3-(4’-nitrophenyl)-1-(2-hydroxyphenyl)-prop-2-ene-1-one : 
               A mixture of 2-hydroxy Acetophenone (0.01) and p-nitro benzaldehyde (0.01) was 
stirred in 30 ml of absolute ethanol (95%) and then aqueous solution of potassium hydroxide 
was added to it. The reaction mixture was kept overnight at room temperature and then 
poured on crushed ice. The mixture was then neutralised with dil.HCl acid. The chalcone 
derivative precipitates out as solid that was filtered dried and recrystallised from ethanol and 
analysed. 
(2-Hydroxy Acetophenone)(4-Nitrobenzaldehyde)                          (2-Hydroxy Chalcone Derivative) 
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STEP 2 : Cylisation of Chalcone Derivative and Addition of Hydroxyl group : 
     Synthesis of 2-(4’-nitrophenyl)-3-hydroxy-4H-Chromen-4-one : 
                The intermediate, add 10 ml of hydrogen peroxide drop wise maintaining 
temperature 10 
o
C, stir for 2 hrs and then poured on crushed ice. The mixture was then 
neutralised with dil.HCl acid. The solid product was filtered, washed with ice cold water. 
 
(2-Hydroxy Chalcone Derivative)                                         2-(4’-nitrophenyl)-3-hydroxy-4H-Chromen-4-one                                                                                                                             
 
STEP-3 : Addition of Iodine : 
 Synthesis of 2-(4’-nitrophenyl)-3-hydroxy-6,8-Diiodo-4H-Chromen-4-one : 
                     The final product is dissolved in 10ml of Methanol,add Potassium 
Hydroxide(25mg) with stirring and add Iodine. Keep solution for room temperature, stir for 3 
hrs. Evaporate the solution to obtain the product. 
 
2-(4’-nitrophenyl)-3-hydroxy-4H-Chromen-4-one                           2-(4’-nitrophenyl)-3-hydroxy-6,8-diiodo  
                                                                                                                               4H-Chromen- 4-one                                                                                                                                                                                                                                                     
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COMPOUND I – Synthesis of 2-(2’-furfural)-3-hydroxy-6,8-diiodo-4H-Chromen-4-one 
STEP 1: Preparation of Chalcone Derivative  
 Synthesis of 3-(2’-furfural)-1-(2-hydroxyphenyl)-prop-2-ene-1-one: 
                A mixture of 2-hydroxy Acetophenone (0.01) and Furfuraldehyde (0.01) was 
stirred in 30 ml of absolute ethanol (95%) and then aqueous solution of potassium hydroxide 
was added to it. The reaction mixture was kept overnight at room temperature and then 
poured on crushed ice. The mixture was then neutralised with dil.HCl acid. The chalcone 
derivative precipitates out as solid that was filtered dried and recrystallised from ethanol and 
analysed. 
(2-Hydroxy Acetophenone)    (Furfuraldehyde)                                    (2-Hydroxy Furfural Chalcone Drv.) 
 
STEP 2 : Cylisation of Chalcone Derivative and Addition of Hydroxyl group : 
Synthesis of 2-(2’-furfural)- 3-hydroxy-4H-Chromen-4-one : 
                  The intermediate, add 10 ml of hydrogen peroxide drop wise maintaining 
temperature 10 
o
C, stir for 2 hrs and then poured on crushed ice. The mixture was then 
neutralised with dil.HCl acid. The solid product was filtered, washed with ice cold water. 
     (2-Hydroxy Furfural Chalcone Drv.)                               2-(2’-fufural)-3-hydroxy-4H-Chromen-4-one) 
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STEP-3: Addition of Iodine: 
 Synthesis of 2-(4’-nitrophenyl)-3-hydroxy-6,8-Diiodo-4H-Chromen-4-one : 
                     The final product is dissolved in 10ml of Methanol,add Potassium 
Hydroxide(25mg) with stirring and add Iodine. Keep solution for room temperature, stir for 3 
hrs. Evaporate the solution to obtain the product. 
 
2-(2’-fufural)-3-hydroxy-4H-Chromen-4-one)                             2-(2’-furfural)-3-hydroxy-6,8-diiodo 
                                                                                                                    4H-Chromen-4-one 
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   6.3 SOLUBILITY STUDIES63, 64 
Table No. 1 
 
 Key:  +++, ++, + → Soluble; - → Insoluble; ± → Sparingly soluble 
 
 
S.No 
SOLVENT 
Water Ethanol Acetone Chloroform Benzene DMSO 
COMPOUND 
1. Intermediate I − + +++ ++ ++ +++ 
2. Intermediate II − + ++ ++ ++ +++ 
3. Intermediate III − + ++ ++ ++ +++ 
4. Intermediate IV − + +++ +++ +++ +++ 
5. Intermediate V − + +++ +++ +++ +++ 
6. Intermediate VI − + +++ +++ +++ +++ 
7. Intermediate VII − + ++ ++ +++ +++ 
8. Intermediate VIII − + +++ +++ ++ +++ 
9. Intermediate IX − + +++ +++ +++ +++ 
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6.4 CHEMICAL CHARACTERIZATION AND SPECTRAL STUDIES FOR 
INTERMEDIATE 
  The structure of all the newly synthesized intermediate was elucidated 
by IR spectra.IR spectra were recorded on Shimadzu FTIR-8400’s 
spectrophotometer. The IR values were measured in cm
-1
and the results are shown 
below. 
1. INTERMEDIATE I: 3-(4-nitrophenyl)-1-(2-hydroxyphenyl)-prop-2-ene-1-
one  
IR (KBr cm
-
1) 3634.97 ( phenolic O-H stretch), 2978.19 ( aromatic C-H stretch), 
1686.81 ( C=O stretch ), 1520.92 (aromatic C=C stretch), 1349.25 ( N=O stretch) 
2. INTERMEDIATE II: 3-(4-chlorophenyl)-1-(2-hydroxy-4-methoxyphenyl)-
prop-2-ene-1-one  
IR (KBr cm
-
1) 2980.12 (aromatic C-H stretch), 1591.33 ( C=O stretch), 1569.14    
(aromatic C=C stretch), 1223.87 (C-O stretch), 789.88 (C-Cl stretch) 
3. INTERMEDIATE III: 3-(2’-furfural)-1-(2-hydroxyphenyl)-prop-2-ene-1-
one  
IR (KBr cm
-
1) 3614.72 (phenolic O-H stretch), 2994.59 ( aromatic C-H stretch), 
1642.44 (C=O stretch), 1554.68 (aromatic C=C stretch), 1214.23 (C-O stretch). 
4. INTERMEDIATE IV: 3-(2’-hydroxyphenyl)-1-(2-hydroxyphenyl)-prop-2-
ene-1-one  
IR(KBr cm
-
1)  3284.88 (phenolic O-H stretch), 1629.90 (C=O stretch), 1584.57 
(aromatic C=C stretch), 1263.42 (C-O stretch). 
5. INTERMEDIATE V: 3-(4-nitrophenyl)-1-(2-hydroxy-4-methoxyphenyl)-
prop-2-ene-1-one  
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IR (KBr cm
-
1)  3526.96 (phenolic O-H stretch), 2921.29 (aromatic C-H stretch), 
1696.45 (C=O stretch), 1523.82 ( aromatic C=C stretch), 1345.39 ( N=O stretch), 
1106.21 ( C-O stretch). 
6. INTERMEDIATE VI: 3-(4-methoxyphenyl)-1-(2-hydroxyphenyl)-prop-2-
ene-1-one  
 IR (KBr cm
-
1) 3563.61 (phenolic O-H stretch), 3025.45 (aromatic C-H stretch), 
2913.57 (alkane C-H stretch), 1639.36 (C=O stretch), 1563.36(aromatic C=C 
stretch), 1030.02 (C-O stretch)  
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6.5 SOLUBILITY STUDIES
63,64
 
 
Table No. 2 
S.No 
SOLVENT 
Water Ethanol Acetone Chloroform Benzene DMSO 
COMPOUND 
1. Compound I − + +++ +++ ++ +++ 
2. Compound II − + +++ ++ ++ +++ 
3. Compound III − + +++ +++ +++ +++ 
4. Compound IV − + +++ ++ +++ +++ 
5. Compound V − + ++ ++ +++ +++ 
6. Compound VI − + +++ ++ ++ +++ 
7. Compound VII − + +++ +++ ++ +++ 
8. Compound VIII − + +++ ++ +++ +++ 
9. Compound IX − + ++ +++ +++ +++ 
 
Key:  +++, ++, + → Soluble; - → Insoluble   ; ± → Sparingly soluble 
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6.6 CHARACTERISATION DATA FOR THE SYNTHESISED COMPOUNDS 
                
Table No. 3 
 
Mobile Phase: Chloroform: Ethyl Acetate: Formic acid (5:4:1) 
 
Sr. 
No. 
Compounds 
Mol. 
Formula 
Mol. 
Weight 
M.P 
( 
o
C) 
Rf 
Value 
% 
Yield 
(w/w) 
Elemental Analysis 
Calculated ( % ) 
C H O N Cl I 
1 A C15H9O5N 283.23 126-128 0.38 83.67 63.61 3.21 28.24 4.94 _ _ 
2 B C16H11O4Cl 302.71 168-170 0.803 72.43 63.48 3.66 21.14 _ 11.72 _ 
3 C C13H8O4 228.2 130-132 0.508 72.92 68.43 3.53 28.04 _ _ _ 
4 D C15H10O4 254.24 136-138 0.396 67.22 70.86 3.96 25.18 _ _ _ 
5 E C16H11O6N 313.26 146-148 0.649 77.27 61.34 3.54 30.64 4.48 _ _ 
6 F C16H12O4 268.26 128-130 0.532 52.97 71.63 4.51 23.86 _ _ _ 
7 G C16H9O6NI2 565.04 140-142 0.54 53.2 34.02 1.61 16.99 2.47 _ 44.91 
8 H C15H7O5NI2 535.02 132-134 0.542 58.62 33.68 1.32 14.96 2.61 _ 47.43 
9 I C13H6O4I2 479.98 138-140 0.448 67.02 32.53 1.26 13.34 _ _ 52.87 
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6.7 SPECTRAL CHARACTERIZATION FOR SYNTHESIZED COMPOUNDS 
Table No. 4 
SR.NO COMPOUNDS IR(KBr) cm
-1
 
1HNMR(δppm) Mass m/z 
1.  A 
3524.06 ( phenolic O-H stretch), 2979.16    ( 
aromatic C-H stretch), 1696.46   ( C=O   stretch ), 
1521.89 (aromatic C=C stretch), 1349.25 ( N=O 
stretch). 
9.704(OH, enol, s), 
7.027-8.308(8H, 
Benzene, m). 
 
282.8531(M
+
), 268.4701, 
234.3168, 147.9133, 
136.0469(
0,2
A
+
), 164.8477 
(
1,3
B
+
), 258.4454(
1,3
A
+
), 
82.5106(
0,4
A
+
). 
2. B 
2980.12 (aromatic C-H stretch), 1591.33    ( C=O 
stretch), 1569.14      ( aromatic  C=C 
stretch),1088.85 (C-O stretch),  759.01 (C-Cl 
stretch). 
9.572(OH, enol, s), 
6.325-8.176(7H, 
Benzene, m), 
3.880(OCH3, s). 
302.0135(M
+
), 281.2148, 
252.0160, 219.0058, 
149.0659, 118.0014(
1,3
B
+
), 
129.0771(
0,2
A
+
), 
209.0679(
1,3
A
+
), 
82.9453(
0,4
A
+
), 
166.0768(M+H-B ring). 
3. C 
3634.97 (phenolic O-H stretch), 3079.46 (aromatic 
C-H stretch), 1668.48     ( C=O stretch), 1556.61 
(aromatic  C=C stretch), 1203.62 (C-O stretch). 
9.543(OH, enol, s), 
6.981-7.938(4H, 
Benzene, m), 
4.025(3H, Furan, m). 
228.1000(M
+
), 212.1622, 
152.4382, 200.0538(
1,3
A
+
), 
133.4982(
0,2
A
+
), 
112.4514(
1,3
B
+
), 
78.5638(
0,4
A
+
), 
66.5681(M+H-A ring) 
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SR.NO COMPOUNDS IR(KBr) cm
-1
 
1HNMR(δppm) Mass m/z 
4. D 
3296.46 ( phenolic O-H stretch), 2956.57 
(aromatic C-H stretch), 1608.69 ( C=O stretch ), 
1563.36 (aromatic C=C stretch), 1285.60 (C-O 
stretch). 
 
9.702(OH, enol, s), 
6.947-8.208(8H, 
Benzene, m). 
255.1000(M
+
), 238.1801, 
222.2249, 149.4613, 
122.5342(
1,3
B
+
), 
135.5544(
0,2
A
+
), 
79.6516(
0,4
A
+
), 
162.489(M=H-B ring).
 
5. E 
3525.99 (phenolic O-H stretch), 1695.49 (C=O 
stretch), 1524.78       ( aromatic C=C stretch), 
1348.39 (N=O stretch ), 1106.21 (C-O stretch). 
 
9.638(OH, enol, s), 
6.672-8.382(7H, 
Benzene, m), 
3.496(OCH3, s). 
307.0275(M
+
), 296.5642, 
252.0160, 220.8764, 
147.2218, 118.0014(
1,3
B
+
), 
136.7824(
0,2
A
+
), 
78.6532(
0,4
A
+
), 
164.2356(M=H-B ring). 
6. F 
3644.62 ( phenolic O-H stretch), 3214.48 
(aromatic C-H stretch), 2950.22 (alkane C-h 
stretch), 1639.55 ( C=O stretch),  1605.79 
(aromatic C=C stretch), 1028.09 ( C-O stretch). 
12.733(OH, enol, s), 
6.915-8.266(8H, 
Benzene, m), 
3.869(OCH3, s). 
 
268.9920(M
+
), 249.3303, 
220.2907, 146.9495, 
135.2109(
0,2
A
+
), 
118.7018(
1,3
B
+
), 
211.5220(
1,3
A
+
), 
79.6628(M+H-B ring). 
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SR.NO COMPOUNDS IR(KBr) cm
-1
 
1HNMR(δppm) Mass m/z 
7. G 
3541.42 ( phenolic O-H stretch), 2997.48 ( 
aromatic C-H stretch), 1693.56   ( C=O stretch), 
1524.78 (aromatic C=C stretch ), 1346.36 ( 
N=O stretch), 1107.18 ( C-O stretch), 719.47 ( 
C-I stretch). 
 
9.542(OH, enol, s), 
6.281-8.384(6H, 
Benzene, m). 
563.5431(M
+
), 547.3876, 
501.5643, 249.4911, 220.5648, 
147.2854, 123.5311(
1,3
B
+
), 
278.5090(
1,3
A
+
), 81.8404(
0,4
A
+
), 
164.4571(M+H-B ring). 
8. H 
3610.86 ( phenolic O-H stretch),2982.05 
(aromatic C-H),1773.61 (aromatic C=C stretch), 
1636.19 ( aromatic C=O stretch), 1520.92 ( 
N=O stretch), 1092.71 ( C-O stretch), 755.16 ( 
C-I stretch). 
9.668(OH, enol, s), 
8.269-8.387(5H, 
Benzene, m). 
543.1000(M
+
), 517.5698, 
468.5626, 220.8973, 149.7674, 
120.0275(
1,3
B
+
), 
388.2298(
0,2
A
+
), 
207.4306(
1,3
A
+
), 84.3313(
0,4
A
+
), 
160.3678(M+H_B ring). 
9. I 
3454.62 ( phenolic O-H stretch ),  2891.39 
(aromatic C-H stretch), 1767.82 (aromatic C=C 
stretch), 1628.94 ( C=O stretch), 1095.60 ( C-O 
stretch), 756.12   (C-I stretch). 
 
9.879(OH, enol, s), 
6.899-8.175(2H, 
Benzene, m), 
3.737(3H, Furan, s). 
478.1000(M
+
), 461.2837, 
216.5885, 149.6342, 
116.8666(
1,3
B
+
), 
385.2983(
0,2
A
+
), 
200.6396(
1,3
A
+
), 88.9546(
0,4
A
+
), 
159.7222(M+H-B ring). 
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6.7.1 Spectral Characterization for Synthesized Compounds 
 
 
Retrocyclization cleavages of the C-ring 
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COMPOUND A: 2-(4’-nitrophenyl)-3-hydroxy-4H-Chromen-4-one 
 
O
O
NO2
OH
 
COMPOUND B: 2-(4-chlorophenyl)-7-methoxy-3-hydroxy-4H-Chromen-4-one 
 
O
O
Cl
OH
H3CO
 
 
COMPOUND C: 2-(2’-furfural)-3-hydroxy-4H-Chromen-4-one 
 
O
O
OH
O
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COMPOUND D: 2-(2’-hydroxyphenyl)-3-hydroxy-4H-Chromen-4-one 
 
 
O
O
OH
OH
 
COMPOUND E: 2-(4’-nitrophenyl)-7-methoxy-3-hydroxy-4H-Chromen-4-one 
 
O
O
NO2
OH
H3CO
 
COMPOUND F: 2-(4’-methoxyphenyl)-3-hydroxy-4H-Chromen-4-one 
 
O
O
OH
OCH3
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COMPOUND G: 2-(4-nitrophenyl)-6,8-diiodo-3-hydroxy-7-methoxy-4H-Chromen-4-one 
 
 
O
O
NO2
OH
H3CO
I
I
 
COMPOUND H: 2-(4’-nitrophenyl)-3-hydroxy-6,8-diiodo-4H-Chromen-4-one 
 
O
O
NO2
OH
I
I
 
COMPOUND I: 2-(2’-furfural)-3-hydroxy-6,8-diiodo-4H-Chromen-4-one 
 
O
O
OH
O
I
I
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7.1 SCREENING OF ANTI-BACTERIAL ACTIVITY 
It is evident from the literature that substituted flavonols exhibits pronounced anti-
microbial activity. Therefore, it has been felt worthwhile to screen the newly synthesized 
compounds for their possible anti-bacterial properties. 
MATERIAL AND METHODS: 
Solutions of all the synthesized compounds were prepared in various concentration using 
DMSO as solvent. Anti-bacterial evaluation of the synthesized compounds were tested against 
both gram negative and gram positive bacteria viz., Bacillus subtitles, Bacillus licheniformis, 
Escherichia coli, Salmonella typhi by using plate hole diffusion method. Streptomycin (1000 
µg/ml) is used as a standard for both gram negative and gram positive bacteria. Effectiveness of 
susceptibility is proportional to the diameter of inhibition of zone was measured. 
EXPERIMENTAL DESIGN FOR ANTI-BACTERIAL STUDIES: 
Cultivation of Microorganism 
The following microorganism was used to study the anti-bacterial activity. Bacterial strains used 
were maintained at 4
o
C on nutrient agar plate before use. 
1. Bacillus subtitles               -    Gram positive bacteria 
2. Bacillus licheniformis       -    Gram positive bacteria 
3. Lacto bacillus                    -    Gram positive bacteria 
4. Staphylococcus aureus      -    Gram positive bacteria 
5. Salmonella typhi               -     Gram negative bacteria 
6. Flavobacterium devorans -     Gram negative bacteria 
7. Escherichia coli                 -    Gram negative bacteria 
8. Klebsiella pneumonia       -     Gram negative bacteria 
Standard: Streptomycin 
 Solvent   : DMSO 
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The medium was prepared by dissolving the specified quantity of the dehydrated medium 
in purified water by heating on a water bath and were dispensed in 100 ml volume conical flasks. 
The conical flasks were closed with cotton plugs and were sterilized by autoclaving at 121
o
C (15 
Ib psig) for minutes. A total of 25 ml of agar medium was poured into sterile universals. The 
Petridish were specially selected with flat bottom and were placed on level surface so as to 
ensure that the layer of medium is in uniform thickness. Each universal was inoculated with 0.2 
ml of different bacterial strains mixed well with the nutrient agar medium into sterile Petri dishes 
and then allowed to solidify
30
. 
A well was prepared in the plate with help of a cork-borer (6 mm) four holes per plate 
were made in set of agar containing a bacterial culture. A total of 0.2 ml test solution of 
synthesized compounds was poured into the wells with the concentrations as 250 µg/ml, 500 
µg/ml and 1000 µg/ml were prepared in DMSO as well as standard (1000 µg/ml), using a 
dropping pipette under aseptic condition and labeled accordingly. The plates were maintained at 
room temperature for 3-5 hrs to allow diffusion of the solution into the medium. The Petri dishes 
used for anti-bacterial screening were incubated 37+ 1
o
C for 24 hrs. the diameter of zones of 
inhibition (mm) surrounding each of the wells was recorded. The results were compared to 
streptomycin (1000 µg/ml) for anti-bacterial activity
30
 
 
 
 
 
 
 
 
 
SCREENING OF ANTI-BACTERIAL ACTIVITY 
 
Nandha College Of Pharmacy And Research Institute, Erode Page 95 
 
Table No. 5 Screening of Synthesized compounds for Anti-bacterial activity 
Compounds 
Concentration 
(μg/ml) 
Zone of Inhibition (mm) 
Gram positive bacteria Gram negative bacteria 
Bacillus 
subtilis 
Bacillus 
licheniformis 
Lacto 
bacillus 
Staphylococcus 
aureus 
Salmonella 
typhi 
Flavobacterium 
devorans 
Escherichia 
coli 
Klebsiella 
pneumonia 
A 
500 14 13 13 12 14 15 14 16 
Std 23 22 20 22 23 24 21 22 
B 
500 17 15 13 14 13 17 15 18 
Std 25 23 20 22 24 25 22 24 
C 
500 16 14 17 15 14 16 14 16 
Std 23 22 21 22 22 24 21 21 
D 
500 15 13 16 14 12 17 16 17 
Std 23 21 22 21 21 23 22 23 
E 
500 17 16 15 13 15 18 17 16 
Std 24 21 23 23 22 23 20 22 
F 
500 18 15 16 13 15 16 16 17 
Std 24 20 21 22 21 22 22 23 
G 
500 19 16 15 14 16 17 17 16 
Std 23 21 22 21 20 24 21 23 
H 
500 18 17 16 16 16 15 16 16 
Std 22 22 21 22 21 22 22 22 
I 
500 18 15 17 15 14 16 15 17 
Std 23 22 22 22 20 21 20 23 
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A) 2-(4’-nitrophenyl)-3-hydroxy-4H-Chromen-4- 
 
 
 
 
one 
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B). 2- (4-chlorophenyl)-7-methoxy-3-hydroxy - 
 
 
 
 
4H-Chromen-4-one 
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C)  2-(2’-furfural)-3-hydroxy- 4 H-Chromen -
 
 
 
 
4 one 
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D)   2-  (2’-hydroxyphenyl)   -3- hydroxy- 4 H-
 
 
 
 
Chromen-4-one 
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E) 2- (4’-nitrophenyl)- 7-methoxy-3-hydroxy- 
 
 
 
 
4 H-Chromen-4-one 
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F) 2 - (4’-methoxyphenyl) - 3-hydroxy - 4 H - 
 
 
 
 
Chromen-4-one 
 
 
 
 
SCREENING OF ANTI-BACTERIAL ACTIVITY 
 
Nandha College Of Pharmacy And Research Institute, Erode Page 102 
 
G) 2- (4-nitrophenyl)-6,8-diiodo-3-hydroxy-7- 
 
 
 
 
methoxy- 4 H- Chromen-4-one 
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H) 2- (4’-nitrophenyl) -3-hydroxy- 6,8-diiodo- 
 
 
 
 
4 H-Chromen-4-one 
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I) 2-(2’-furfural) - 3-hydroxy- 6,8-diiodo -4H- 
 
 
 
 
Chromen-4-one 
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7.2 ANTI-INFLAMMATORY ACTIVITY  
7.2.1 In vitro Albumin Denaturation Method
65,66
 
 The synthesized compounds were screened for anti-inflammatory activity using 
inhibition of albumin denaturation technique. The standard drug and test compounds were 
dissolved in minimum quantity of dimethyl formamide (DMF) and diluted with phosphate buffer 
(0.2M,pH 7.4). 
           Final concentration of DMF in a all solution was less than 2.5%. Test solution (1 ml) 
containing different concentrations of drug was mixed with 1 ml of 1mM albumin solution in 
phosphate buffer and incubated at 27
o
 + 1
o 
C for 15 minutes. Denaturation was induced by 
keeping the reaction mixture at 60
o
 + 1
o 
C in water bath for 10 minutes. 
          After cooling, the turbidity was measured at 660 nm. Percentage inhibition of denaturation 
was calculated from control where no drug was added. Each experiment was done in triplicate 
and average is taken. The Ibuprofen was used as standard drug. 
          The percentage inhibition of denaturation was calculated by using following formula. 
              % of Inhibition = 100 X  ( Vt / Vc – 1) 
     Where, Vt = Mean absorbance of test sample. 
                 Vc = Mean absorbance of control. 
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Table No. 6 Screening of in-vitro anti-inflammatory activity. 
 
Compounds 
Concentration 
(μg/ml) 
Absorbance 
Inhibition of denaturation 
(%) 
Control 
----- 0.096 ----- 
A 
100 0.131 36.45 
500 0.171 78.12 
B 
100 0.134 39.58 
500 0.169 76.04 
C 
100 0.120 25.00 
500 0.159 65.62 
D 
100 0.118 22.91 
500 0.157 63.54 
E 
100 0.124 29.16 
500 0.166 72.91 
F 
100 0.114 18.75 
500 0.167 73.95 
G 
100 0.126 31.25 
500 0.165 71.87 
H 
100 0.132 37.50 
500 0.169 76.04 
I 
100 0.118 22.91 
500 0.161 67.70 
Standard 
(Ibuprofen) 
200 0.188 95.83 
 
All newly synthesized compounds shows good invitro anti-inflammatory activity. 
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In vivo Carrageenan-Induced Paw Edema in rats
69
 
Male Wistar albino rats (120-150g) were used in the study, the male rats were divided 
into four groups (n = 6). The first group received 0.5% CMC (10ml/ kg p.o.), while the second 
group received indomethacin at the dose level of 10 mg/kg p.o. body weight. The different 
synthesized compounds at the dose of 50 mg/kg body weight were administered orally to the 
treated group. Paw edema was induced by the injection of 0.1 ml of 1% freshly prepared 
suspension of carrageenan into the sub-planter region of the left hind paw of the each group of 
rat after 30 min. The paw thickness was measured at 0 min, 60 min, 120 min, and 180 min after 
carrageenan injection by using verniar calipers. The difference between 0 h and subsequent 
readings were considered as edema volume. The percentage inhibition of edema in various 
groups was calculated using the formula. 
The % inhibition of edema was calculated by following formula.  
 
 
                                                      (Vt-Vo) control - (Vt-Vo) treated  
% Inhibition of Paw edema = -------------------------------------------------- x 100  
                                                                  (Vt-Vo) control  
 
Where,  
Vt = Paw thickness after carrageenan injection.  
V0 = Paw thickness before carrageenan injection.  
The one way ANOVA test followed by Dunnets t test performed by using Graph pad Insat 
software. The results obtained are showed in the Table. 
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Table No. 7  Anti-inflammatory activity of compounds in carrageen induced inflammation 
in rat model. 
Treatment 
% Inflammation at the time of intervals Percentage of 
Inhibition 0 (h) 3 (h) 
Control  (Vehicle) 
0.5 % CMC (10 mg/ kg p.o) 
2.76 + 0.006 3.86 + 0.0011 _ 
Standard (Indomethacin)       
(10 mg/kg) 
2.58 + 0.023 2.81 + 0.05
* 
79.09 
Compound A 2.65 + 0.01 2.95 + 0.02
* 
70.90 
Compound B 2.56 + 0.08 2.90 + 0.02
* 
69.09 
Compound C 2.54 + 0.14 2.96 + 0.12
* 
61.89 
Compound D 2.36 + 0.01 2.98 + 0.07
* 
57.27 
Compound E 2.25 + 0.14 2.85 + 0.09
* 
63.63 
Compound F 2.58 + 0.18 2.95 + 0.12
* 
66.36 
Compound G 2.40 + 0.08 2.81 + 0.1
* 
62.72 
Compound H 2.51 + 0.21 2.83 + 0.12
* 
70.90 
Compound I 2.48 + 0.18 2.94 + 0.09
* 
59.09 
 
Value expressed as mean ± SEM, *P<0.05 compared with control.  
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Figure No. 1 Anti-inflammatory activity of Synthesized compounds 
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7.3 ANTI-DIABETIC ACTIVITY 
Selection of animals 
Wistar Albino Rats (Male) weighing around 150-200 gm was selected for the experiment. 
The animals were checked for the free of any disease, only healthy rodent is accepted for the 
experiments. The male rodents are preferred so that there occurs no interference in between the 
experiment because of the pregnancy. The rodents are collected from the animal house of 
Nandha College of pharmacy and Research Institute, Erode 52. 
Maintenance of animals 
The selected rodents are brought to the laboratory two days before the commencement of 
the experiment and provided with standard laboratory rodent chow diet obtained from and free 
access of water, 12hrs day/ dark cycle and room temperature is maintained 27
o
C. The night 
before the commencement of the experiment food is withdrawn but free access of water is 
provided. 
Induction of Diabetes 
The acclimitatized animals were kept fasting for 24 hrs with water and the initial blood 
glucose levels were checked and injected with alloxan 150mg/kg dose by intra peritoneal route in 
normal saline. The blood glucose levels were checked after 72 hrs of alloxan injection. The 
animals were considered diabetic when the blood glucose level was raised beyond the 200 
mg/dL; this condition was observed at the end of 72 hrs after alloxan injection.  
Experimental procedure
68 
After confirmation of increased hyperglycemia the diabetic rats were divided into 
different groups as mentioned below. 
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Groupings of animals 
Group I    =       Control (Normal saline- 1ml/kg) 
Group II    =       Diabetic Control  (Alloxan 150mg/kg) 
Group III   =       Compound F (200 mg/kg) 
Group IV   =       Compound D (200 mg/kg) 
Group V            =      Compound B (200 mg/kg) 
Group VI          =       Compound A (200 mg/kg) 
Group VII   =      Glibenclamide (5 mg/kg) 
The drugs were dissolved in normal saline and it was administered orally. Anti-
hyperglycemic activity in diabetic rats was assessed by fall in Fasting Blood Glucose level. 
Blood samples were collected from the tip of the tail on 0
th
, 1st, 2nd, 3rd week.  By without 
sacrificing the animals, from the tail vein by snipping off the tip of the tail and blood glucose 
were checked. The biochemical parameters, Cholesterol, Triglycerides, Total protein are 
determined by using the commercial kit (Ecoline, Manufactured by Merck Specialties, Private 
limited, Ambernath). 
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Table No. 8 The effect of Synthesized compounds on fasting blood glucose level in Alloxan 
induced Diabetic rats 
SR.NO Groups 1
st
 week 2
nd
 week 3
rd
 week 
1 Normal control 98.83 + 6.416
** 
97.16 + 5.056
** 
101 + 7.572
** 
2 Diabetes control 255 + 6.851 270 + 6.552 297.5 + 5.737 
3 Derivative- I 189.5 + 7.329
** 
163.3 + 5.602
** 
142.6 + 6.546
** 
4 Derivative-II 214.6 + 5.875
** 
163.3 + 5.602
** 
142.6 + 6.546
** 
5 Derivative-III 214.6 + 9.305
** 
183.83 + 9.655
** 
155.6 + 3.703
** 
6 Derivative-IV 216.83 + 8.920
** 
188.83 + 3.790
** 
160.3 + 5.765
** 
7 Standard 183.83 + 5.307
** 
149.3 + 5.283
** 
139.16 + 4.453
** 
Data represents mean ± SEM. (n=6); *p<0.05; **p<0.01  
Table No. 9 Effect of Synthesized compounds on RBC, WBC and Hemoglobin of control 
and experimental rats 
SR.NO Groups 
RBC 
( mm
3 
X 10
6
) 
WBC 
( mm
3
) 
Hemoglobin 
(g dL
-1
) 
1. Normal control 5.725 + 0.015
* 
5.106.16 + 10.26
** 
9.016 + 0.06
** 
2. Derivative- I 6.05 + 0.076
* 
6873.33 + 12.29
* 
10.016 + 0.06
* 
3. Derivative-II 6.051 + 0.04
* 
6156.66 + 14.29
** 
9.8 + 0.057
* 
4. Derivative-III 6.041 + 0.035
* 
5806.66 + 15.42
** 
9.6 + 0.051
** 
5. Derivative-IV 5.905 + 0.007
* 
5493.33 + 15.42
** 
9.1 + 0.057
** 
 
Data represents mean ± SEM. (n=6); *p<0.05; **p<0.01  
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Table No. 10 Effect of Synthesized compounds on Cholesterol, Triglyceride and Total 
protein of control and experimental rats 
SR.NO Groups 
Cholesterol 
(mg/dl) 
Triglyceride 
(mg/dl) 
Total protein 
(g/dl) 
1. Normal control 108.78 + 4.78 78.35 + 3.01 7.98 + 1.41 
2. Derivative- I 114.57 + 5.03
* 
81.34 + 3.67
* 
7.21 + 1.21
* 
3. Derivative-II 118.28 + 4.56
* 
83.69 + 4.01
* 
6.94 + 1.01
* 
4. Derivative-III 122.93 + 4.02
* 
89.04 + 3.68
* 
6.35 + 0.78
* 
5. Derivative-IV 124.27 + 3.89
* 
91.82 + 3.98
* 
5.88 + 0.67
** 
 
Data represents mean ± SEM. (n=6); *p<0.05; **p<0.01  
Table shows the blood glucose levels in rats of different groups. The glucose level was 
significantly high in Alloxan treated group when compared to that of control and drug treated 
group. On repeated administration of the test drugs and standard drug for 21 days, a significant 
decrease in glucose level was observed in diabetic rats. The others biochemical parameters like 
RBC, WBC and Hemoglobin were found to be increased. The Cholesterol and Triglyceride were 
also found to be increased while the Total protein were decreased. 
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8. RESULT AND DISCUSSION 
  The synthesis of various substituted 3-hydroxy flavones (Compound I to IX) was 
about 53-83 % yield and was characterized, by the following steps:- 
a) Step I - Various acetophenone derivatives like 2-hydroxy acetophenone, p-methoxy-
hydroxy acetophenone were treated with various aldehydes such as p-nitrobenzaldehyde, 
p-chlorobenzaldehyde, furfuraldehyde, anisaldehyde, salicylaldehyde to give respective 
chalcone derivatives. 
b) Step II - Different chalcone derivatives thus obtained were further condensed in presence 
of hydrogen peroxide and ethanol to yield the desired compounds. 
c) Step III - The final flavonol derivative was treated with iodine in presence of methanol to 
yield the desired compounds. 
 
The Synthesized Compounds were screened for anti-diabetic axtivity. The Compounds F, 
D, C shows significant activity as compared with that of standard drug. The Compounds having 
p-methoxy phenyl, 2-hydroxy phenyl and furfural at 2
nd
 position shows better activity when 
compared with standard Glibenclamide. 
Screening of Synthesized Compounds for anti-bacterial activity shows good result from the data 
mentioned in table no.5. The Compound B, C, F, I afforded better anti-bacterial activity against 
Gram positive Bacillus substilis, Staphylococcus aureus while Compounds B, F were found 
potent against Gram negative Escherichia coli, Flavobacterium devorans and Klebsiella 
pneumonia when compared with standard Streptomycin. 
The Synthesized compounds evaluated anti-inflammatory activity by in vitro and in vivo. The 
data summarized in table no.6 gives result of in vitro anti-inflammatory activity the A, B, E, F, H 
shows good activity when compared with standard Ibuprofen. The data summarized in table no.7 
revaluate the results of in vivo anti-inflammatory activity where the Compound A, B, F, H shows 
good activity when compared to standard Indomethacin. 
All the newly synthesized compounds were then identified for their structure and 
functional groups by using various analytical studies like IR, Mass, 
1HNMR spectra’s. All the 
newly synthesized compounds were screened to in vitro antimicrobial to various gram positive 
and gram negative bacteria’s using well plate agar diffusion technique by measuring inhibition 
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zone in millimeters. The anti-inflammatory activity was performed in- vivo and in-vitro. In- 
vitro, the albumin denaturation technique was used. The Ibuprofen was used as a standard. 
While, in vivo was performed by carrageenen induced paw edema method. The Indomethacin 
was used as standard. The both results were correlated by percentage of inhibition. All the 
synthesized compounds show good anti-inflammatory activity.  It is also pharmacological 
evaluated the synthesized compounds found to be exhibit potent anti-hyperglycemic activity 
when compared with that of the anti-hyperglycemic standard Glibenclamide at a concentration of 
5 mg/kg. 
Inflammation is a local response of living mammalian tissues to the injury. It is a body 
defense reaction in order to eliminate or limit the spread of injurious agents. There are various 
components to an inflammatory reaction that can contribute to the associated symptoms and 
tissue injury. Oedema formation, leukocyte infiltration and granuloma formation represent such 
components of inflamemation
70
. Oedema formation in the paw is the result of a synergism 
between various inflammatory mediators that increase vascular permeability or the mediators 
that increase blood flow
69
. Several experimental models of paw oedema have been described. 
Carrageenan-induced paw oedema is widely used for determining the acute phase of 
inflammation. Histamine, 5-hydroxytryptamine and bradykinin are the first detectable mediators 
in the early phase of carrageenan-induced inflammation whereas prostaglandins are detectable in 
the late phase of inflammation
71
. 
 
It is well known that carrageenan induced paw edema is characterized by biphasic event 
with involvement of different inflammatory mediators. In the first phase (during the first 2 h after 
carrageenan injection), chemical mediators such as histamine and serotonin play role, while in 
second phase (3 – 4 h after carrageenan injection). Kinin and prostaglandins are involved75. Our 
results revealed that administration of  Synthetic  Compounds A, B, E, F, H inhibited the oedema 
starting from the first hour and during all phases of inflammation, which is probably inhibition of 
different aspects and chemical mediators of inflammation. 
 
Protein denaturation has been employee as an in vitro screening method for anti-
phlogistic agents by Mizushima and his co-workers also confirmed their work and reported that 
anti-inflammatory drug, inhibit protein denaturation
76,77,78
. Drug binding to plasma albumin may 
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inhibit thermal denaturation of albumin which perhaps block Ǿ -NH 2 groups in case of histidine 
decarboxylase or may displace urate from albumin. All compounds (0.20 mM) showed ability to 
denature bovine serum albumin, as observed in in- vitro inhibition studies.  Denaturation of 
proteins is a well documented cause of inflammation. As part of the investigation on the 
mechanism of the anti inflammation activity, ability of synthesized compound.  Protein 
denaturation was studied. It was effective in inhibiting heat induced albumin denaturation. As 
protein denaturation is implicated in inflammation, some compounds which showed good 
inhibition of denaturation were tested in vivo for anti-inflammatory activity by carrageenan 
induced edema in the rat paw
71
. 
 
The synthesized may possibly inhibit the release of lysosomal content of neutrophils at 
the site of inflammation. These neutrophils lysosomal constituents include bactericidal enzymes 
and proteinases, which upon extracellular release cause further tissue inflammation and 
damage
73
. Proteinases have been implicated in arthritic reactions. Neutrophils are known to be a 
source of proteinase which carries in their lysosomal granules many serine proteinases. It was 
previously reported that leukocytes proteinase play important role in the development of tissue 
damage during in inflammatory reactions and significant level of protection was provided by 
proteinase inhibitors
74
. Recent studies have shown that many flavonoids and related polyphenols 
contributed significantly to the antioxidant and antinflammatory activities of many plants. 
Alloxan is the most commonly employed agent for the induction of experimental diabetic 
animal models of human insulin-dependent diabetes mellitus. Alloxan causes diabetes through its 
ability to destroy the insulin producing beta cells of the pancreas I studies have shown that 
alloxan is selectively toxic to pancreatic beta cells, leading to the induction of cell necrosis.  
There is increasing evidence that alloxan caused diabetes by rapid depletion of a cells, by 
DNA alkylation and accumulation of cytotoxic free radicals that is suggested to result from 
initial islet inflammation, followed by infiltration of activated macrophages and lymphocyte in 
the inflammatory focus. It leads to a reduction in insulin release there by a drastic reduction in 
plasma insulin concentration leading to stable hyperglycemic states
72
. In this study significant 
hyperglycemia was achieved within 48 hours after alloxan (150mg/kg b.w. i.p) injection. 
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Alloxan induced diabetic rats with more than 200mgdl of blood glucose were considered to be 
diabetic and used for the study. 
. 
Some of the newly synthesized substituted flavonol derivatives were active anti 
hyperglycemic agent when studied at 200 mg/kg concentration. The evaluated 3-hydroxy 
flavones derivatives have activity during 21 days whereas F,  D, C showed better activity then 
other compounds, administration of drug in alloxan induced hyperglycemic rats when compared 
to the standard and control used in the study. 
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9. SUMMARY AND CONCLUSION 
The present study was carried out to synthesize and to screen the newly developed 
compounds for its pharmacological activity. First attempt of the study was to synthesize the 
substituted 3-hydroxy flavone derivatives by the Algar-Flynn-Oyamada reaction between 
acetophenone derivatives like 2-hydroxy acetophenone, 2-hydroxy p-methoxy acetophenone and 
various aldehydes such as p-nitro benzaldehyde, p-chlorobenzaldehyde, furfuraldehyde, 
salicylaldehyde, anisaldehyde, to give chalcone products which further condenses in presence of 
hydrogen peroxide and ethanol to yield the desired flavanol derivatives. Both analytical and 
spectral data (IR, MS, 
1
HNMR) of all the synthesized compounds were in full agreement with 
the synthesized structure.  
Flavonoids and phenolic acids have protective role in carcinogenesis, inflammation, 
atherosclerosis, thrombosis and have high antioxidant capacity. Furthermore, flavonoids have 
been reported as aldose reductase inhibitors blocking the sorbitol pathway that is linked to many 
problems associated with diabetes. 
Research on flavonoids received an added impulse with the discovery of the French 
paradox, ie, the low cardiovascular mortality rate observed in Mediterranean populations in 
association with red wine consumption and a high saturated fat intake. The flavonoids in red 
wine are responsible, at least in part, for this effect. Furthermore, epidemiologic studies suggest a 
protective role of dietary flavonoids against coronary heart disease. The association between 
flavonoid intake and the long-term effects on mortality was studied subsequently and it was 
suggested that flavonoid intake is inversely correlated with mortality due to coronary heart 
disease. An important effect of flavonoids is the scavenging of oxygen-derived free radicals. In 
vitro experimental systems also showed that flavonoids possess anti-inflammatory, anti-allergic, 
antiviral, and anti-carcinogenic properties.  
During the synthetic work the classical preparative organic chemical methods have been 
applied. The monitoring of the reaction was checked by TLC. Structure elucidation of newly 
obtained compounds was proved on the basis of the NMR, MS, IR spectra. Chromen-4-ones 
have been reported to have various pharmacological activities. However, in this study we have 
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evaluated the compounds (Chromen-4-one) for its in-vitro anti-inflammatory, anti-
hyperglycemic and anti-microbial activity. The in-vivo studies conducted on the alloxan induced 
diabetes rats indicate that the substituted 3-hydroxy flavones have exhibited marked anti-
hyperglycemic activity. The evaluated compounds have better anti hyperglycemic activity for 21 
days of drug administration and the compounds like F, D, C showed better activity while other 
compounds exhibited mild anti hyperglycemic activity. Whereas  compounds B, C, F, I  afforded 
better antimicrobial activity against gram positive Bacillus substilis, Staphylococcuss aureus 
compound B, F were found to exhibit potent activity against gram negative Escherichia coli, 
Flavobacterium devorans and Klebsiella pneumonia. The all newly synthesized compounds 
shows good in vitro and in vivo anti-inflammatory activity. After comparing the results from 
pharmacological screening of compounds A to I, it was concluded that the incorporation of a 
substituited phenyl and furyl moiety in 3-hydroxy flavone or flavanol ring enhances their 
pharmacological activity. The activity of the compounds depends upon the nature and the 
position of the substitution at 3 and 7 of chromen-4-one moiety. Also,  the substitution with p-
nitrophenyl, p-chlorophenyl, furyl, 2-hydroxyphenyl and p-methoxyphenyl at the 2
th
 position and 
7
th
 position with methoxy, showed pronounced in-vitro anti-inflammatory, anti hyperglycemic 
and antimicrobial activity.  
          The mechanisms and the sequence of events by which free radicals interfere with cellular 
functions are not fully understood, but one of the most important events seems to be lipid 
peroxidation, which results in cellular membrane damage. This cellular damage causes a shift in 
the net charge of the cell, changing the osmotic pressure, leading to swelling and eventually cell 
death. Free radicals can attract various inflammatory mediators, contributing to a general 
inflammatory response and tissue damage. To protect themselves from reactive oxygen species, 
living organisms have developed several effective mechanisms. The antioxidant-defense 
mechanisms of the body include enzymes such as superoxide dismutase, catalase, and glutatione 
peroxidase, but also nonenzymatic counterparts such as glutathione, ascorbic acid, and α-
tocopherol. The increased production of reactive oxygen species during injury results in 
consumption and depletion of the endogenous scavenging compounds. Flavonoids may have an 
additive effect to the endogenous scavenging compounds. Flavonoids can interfere with ≥3 
different free radical–producing systems, which are described below, but they can also increase 
the function of the endogenous antioxidants.   The present study on the evaluation of 4-flavones 
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derivatives (flavanol) were found in significant activity of in vitro and in vivo anti-inflammatory, 
anti-microbial and anti-hyperglycemic. The study of flavonoids is complex because of the 
heterogeneity of the different molecular structures and the scarcity of data on bioavailability. 
Furthermore, insufficient methods are available to measure oxidative damage in vivo and the 
measurement of objective endpoints remains difficult. There is a need to improve analytic 
techniques to allow collection of more data on absorption and excretion. Data on the long-term 
consequences of chronic flavonoid ingestion are especially scarce. In conclusion, the in vivo 
studies that have been performed do give a hopeful picture for the future 
On the basis of order of pharmacological studies of test compounds the following structure 
activity relationship (SAR) was observed 
1. At C-2, p-nitrophenyl, p-chlorophenyl, p-methoxyphenyl, p-hydroxyphenyl substitution 
showed the best activity followed by furyl substitution. 
2.  Non substitution of flavonol ring at C-7 was less favorable for the activity than C-7 
methoxy and 6,8 di-iodo substitution. 
3. At C-4’ substitution of C-2 phenyl ring was more favorable. 
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